Sugi Predict

Sugi Predict / Compounds / SCHEMBL3960904

SCHEMBL3960904

SCHEMBL3960904

CC(C)CN1CCC(N)CC1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GNAI3 P08754 2/20 0.44
▸ GNAO1 P09471 2/20 0.44
▸ GNAI1 P63096 2/20 0.44
▸ PIK3CD O00329 4/20 0.43
▸ HRH3 Q9Y5N1 1/20 0.39
▸ CYP2D6 P10635 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ SPHK1 Q9NYA1 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ PARP2 Q9UGN5 1/20 0.34
▸ ROCK2 O75116 1/20 0.33
▸ ROCK1 Q13464 1/20 0.33
▸ ERBB2 P04626 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3544692 0.98 GNAI3 (0.47) GNAI3GNAO1GNAI1PIK3CDHRH3
Hydrochloric Acid SCHEMBL4641642 0.98 GNAI3 (0.47) GNAI3GNAO1GNAI1PIK3CDHRH3
Hydrochloric Acid SCHEMBL3262585 0.87 OPRM1 (0.40) GNAI3GNAO1GNAI1PIK3CDHRH3
SCHEMBL12932725 0.86 PIK3CD (0.45) GNAI3GNAO1GNAI1PIK3CDHRH3
SCHEMBL17149321 0.86 PIK3CD (0.45) GNAI3GNAO1GNAI1PIK3CDHRH3
SCHEMBL19069226 0.86 PIK3CD (0.45) GNAI3GNAO1GNAI1PIK3CDHRH3
SCHEMBL21311463 0.83 PIK3CD (0.45) PIK3CDHRH3CYP2D6SMN1; SMN2KDM4E
Trifluoroacetic Acid SCHEMBL16114304 0.82 PIK3CD (0.42) PIK3CDHRH3CYP2D6SMN1; SMN2KDM4E
SCHEMBL5780737 0.82 GNAI3 (0.41) GNAI3GNAO1GNAI1SPHK1KDM4E
Hydrochloric Acid SCHEMBL2291615 0.80 GNAI3 (0.44) GNAI3GNAO1GNAI1SPHK1ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451185-B1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2014-08-06 — — EP claimed
US-6906084-B2 Indole derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-06-14 — — US claimed
JP-2005514365-A — — 2005-05-19 — — JP claimed
EP-1451185-A1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS Aventis Pharma Deutschland GmbH (DE) 2004-09-01 — — EP claimed
US-20030199689-A1 New indole derivatives as factor Xa inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-10-23 — — US claimed
WO-2003044014-A1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-05-30 — — WO claimed
CN-116354923-B Nitrogen-containing heterocyclic compound and application thereof 江苏恩华药业股份有限公司 2025-05-09 — — CN disclosed
WO-2024150963-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 광주과학기술원 2024-07-18 — — WO disclosed
US-11827638-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JANSSEN PHARMACEUTICA NV (BE) 2023-11-28 — — US disclosed
US-11713320-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-08-01 — — US disclosed
US-11713320-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-08-01 — — US disclosed
US-11713320-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-08-01 — — US disclosed
CN-116354923-A Nitrogen-containing heterocyclic compound and application thereof 江苏恩华药业股份有限公司 2023-06-30 — — CN disclosed
US-20090069565-A1 NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-03-12 — — US disclosed
US-6906084-B2 Indole derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-06-14 — — US disclosed
US-20050043302-A1 New indole derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-02-24 — — US disclosed
EP-1451185-A1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS Aventis Pharma Deutschland GmbH (DE) 2004-09-01 — — EP disclosed
US-20030199689-A1 New indole derivatives as factor Xa inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-10-23 — — US disclosed
WO-2003044014-A1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-05-30 — — WO disclosed
US-4153702-A Basically alkylated dithiosalicyclic acid amides and their use as medicaments BAYER AKTIENGESELLSCHAFT (DE) 1979-05-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069565-A1 NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS F12, F5, F2 GNAI3 1561/4885GNAO1 2303/4885GNAI1 1227/4885
US-11827638-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JAK1, JAK2, JAK3 GNAI3 948/4885GNAO1 2603/4885GNAI1 932/4885
US-11713320-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof DYRK1A, WNT3, DYRK3 GNAI3 1473/4885GNAO1 1989/4885GNAI1 2207/4885
US-20030199689-A1 New indole derivatives as factor Xa inhibitors F5, F12, F2 GNAI3 1353/4885GNAO1 2313/4885GNAI1 1151/4885
US-20050043302-A1 New indole derivatives as factor Xa inhibitors F12, F5, F2 GNAI3 1663/4885GNAO1 2501/4885GNAI1 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.